This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
Secondary malignancies due to alkylating agents or topoisomerase II inhibitors are a concern in patients treated for primary brain tumors of the nervous system. Myelosuppression is the dose-limiting toxic effect of the alkylating agent temozolomide; reversible hematologic toxicity consisting mainly of thrombocytopenia is reported to occur in 7% of patients treated with concomitant radiotherapy and temozolomide and 14% with adjuvant temozolomide.1 However, the incidence of secondary malignancies and nonreversible hematologic disorders, such as myelodysplastic syndrome, are a rare complication of temozolomide.2
Footnotes
Author contributions: Dr. Clark, Dr. Taylor, and Daphne Wang compiled the data. Dr. Clark, Dr. Abramson, and Dr. Batchelor wrote the article.
Study funding: No targeted funding reported.
Disclosure: The authors report no disclosures relevant to the manuscript. Go to Neurology.org for full disclosures.
- Received October 19, 2012.
- Accepted in final form February 28, 2013.
- © 2013 American Academy of Neurology
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Efficacy of Ubrogepant in the Acute Treatment of Migraine With Mild Pain vs Moderate or Severe Pain
Dr. Kathleen Digre and Dr. Kendra Pham
► Watch
Topics Discussed
Alert Me
Recommended articles
Limited role for extended maintenance temozolomide for newly diagnosed glioblastoma
Romiplostim for temozolomide-induced thrombocytopenia in glioblastoma
Prolonged survival with valproic acid use in the EORTC/NCIC temozolomide trial for glioblastoma
Safety and feasibility of long-term temozolomide treatment in patients with high-grade glioma